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Antibiotic therapy in acute diarrhea
associated with Shigella:
what is the best option?
Dear Editor,
Nunes et al.1 highlight the finding of 77.1% of bacterial 
resistance in Shigella samples isolated from children with acute 
diarrhea in Teresina, state of Piauí, Brazil.1
International and national guidelines recommend antibiotics 
as a supplementary measure in the treatment of children with 
acute diarrhea and blood in stool (dysentery presumably caused 
by Shigella),2-4 respecting the profile of regional sensibility to 
antimicrobials.2,3 However, usually antimicrobials are prescribed 
before the results of coproculture and antibiogram are available. 
In Brazil, combined trimethoprim-sulfamethoxazole therapy is 
recommended for diarrhea caused by Shigella.4
The World Health Organization (WHO)2 recommends the 
use of ciprofloxacin at any age. 
As options, other fluoroquinolones are suggested, as well as 
ceftriaxone in cases of multidrug resistance. Azithromycin is an 
alternative option in adults.2 The European Society for Paediatric 
Gastroenterology, Hepatology and Nutrition (ESPGHAN)3 
recommends azithromycin as a first choice, and third-generation 
cephalosporin (ceftriaxone), nalidixic acid, and fluoroquinolones 
as alternative options. Fluoroquinolones are reserved for patients 
over 17 years old.3 Neither WHO2 nor ESPGHAN3 recommend 
the use of trimethoprim-sulfamethoxazole.
The Office of Health Surveillance of the Brazilian Ministry of 
Health4 recommends trimethoprim-sulfamethoxazole as the first 
choice in severe cases of Shigella infection. The prescription of 
quinolones is reserved for cases of bacterial resistance and is 
contraindicated in children and pregnant women.4
In this context, in 2011, we decided to conduct a literature 
review in the MEDLINE and LILACS databases on the susceptibility 
to trimethoprim-sulfamethoxazole of Shigella samples isolated 
in Brazil. Five articles were retrieved, published between 1995 
and 20065-9; all of them had antibiograms performed by the 
disk method.
The Shigella samples analyzed in those articles,5-9 together 
with the ones analyzed in the article published in Jornal de 
Pediatria,1 totalize 658. Of these, 86.6% (570/658) were 
resistant to trimethoprim-sulfamethoxazole. Resistance 
to other antibiotics was as follows: 50.0% (330/658) for 
ampicillin, 7.0% (47/658) for ceftriaxone, 4.7% (22/465) 
for nalidixic acid, and 1.0% (6/552) for ciprofloxacin. Thus, 
considering in vitro sensitivity results, it is possible to infer 
that the trimethoprim-sulfamethoxazole association should 
not be used to treat infections by Shigella. As a result, one 
question remains: what is the best antimicrobial available to 
treat Shigella infections?
Considering that the samples of Shigella in Brazil were not 
tested for azithromycin and that about 90% were resistant 
to trimethoprim-sulfamethoxazole, it can be concluded that 
the best therapeutic options are nalidixic acid (55 mg/kg/
day divided into four oral doses) and ceftriaxone (50-100 
mg/kg/day intravenously or intramuscularly for 3-5 days). 
WHO recommends the use of ciprofloxacin rather than 
nalidixic acid due to its low cost (open patent), ease of 
administration (two rather than four oral doses), absence 
of quinolone-induced arthropathy seen in animals but not in 
humans, and also because nalidixic acid-resistant Shigella 
strains may show cross-resistance to ciprofloxacin and other 
quinolones in areas where nalidixic acid is used as the first 
choice. However, ciprofloxacin has not been approved for 
pediatric use in Brazil.
In our experience, especially in hospitalized cases with 
acute dysentery, ceftriaxone has been used for a few years 
already.
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Authors’ reply
Dear Editor,
There is a consensus that, although shigellosis is often 
self-limited and successfully treated with fluid and electrolyte 
replacement therapy only, more severe cases of dysentery 
require the administration of antimicrobials, especially 
undernourished patients or those with a compromised immune 
system. In fact, the World Health Organization recommends 
early establishment of antibiotic therapy directed against 
Shigella for individuals with inflammatory diarrhea.1
In Brazil, the Ministry of Health still recommends the 
trimethoprim-sulfamethoxazole association as the first choice 
treatment for patients with shigellosis whenever the use of 
antimicrobial drugs is indicated. In cases of bacterial resistance, 
quinolones should be used, but these are non indicated for 
pregnant woman and children.2
Carrari et al.3 described the use of ceftriaxone for the 
treatment of patients hospitalized with dysentery, given the 
high rates of trimethoprim-sulfamethoxazole resistance found 
by those authors. Indeed, a high prevalence of Shigella samples 
that are resistant to this association of antimicrobials has been 
observed in different regions of Brazil.4-8 Thus, considering 
the great possibility of therapy failure when trimethoprim-
sulfamethoxazole association is employed for patients with 
Shigella dysentery, other options should be considered.
In Brazil, S. sonnei and S. flexneri are almost exclusively 
observed. Our results corroborate data found in the literature, 
which show that the distribution of Shigella species in different 
Brazilian regions is uneven. We observed a predominance 
(≈ 80%) of S. flexneri among children with shigellosis in 
Teresina,9 while in Belo Horizonte, S. sonnei was associated 
with almost 90% of the cases.10
In addition, our experience points to differences in the 
antimicrobial susceptibility profiles of S. sonnei and S. flexneri. 
All samples included in our study groups were susceptible 
to nalidixic acid, ceftriaxone, and ciprofloxacin. Regarding 
trimethoprim-sulfamethoxazole and ampicillin, rates of about 
85 and 100% were observed for S. sonnei, and of 50 and 
70% for S. flexneri, in southeastern and northeastern Brazil, 
respectively. Ampicillin resistance, in turn, was not found in any 
sample of S. sonnei and in approximately 65% of S. flexneri 
strains in the state of Piauí; in Minas Gerais, resistance rates 
of approximately 15 and 100% were observed for S. sonnei 
and S. flexneri, respectively.9,10
According to the recommendation of the Brazilian Ministry 
of Health, antimicrobial drugs should be indicated for the 
treatment of patients with shigellosis regardless of diagnostic 
confirmation via coproculture and antibiogram.2 Taking into 
consideration that, in most cases, treatment is initiated prior 
to a result of a coproculture – a poorly sensitive, expensive 
and time-consuming test – and thus without the establishment 
of the antimicrobial susceptibility profile of the etiologic 
agent in question, safe treatment options, based on local 
epidemiological data, should be adopted.
In this scenario, nalidixic acid, ceftriaxone, and ciprofloxacin 
emerge as suitable options; treatment definition should be 
based on the particularities of each patient. Ceftriaxone is 
available only in an parenteral formulation, and therefore it 
is more suitable for hospitalized patients; however, the high 
cost of this antimicrobial and the scarcity of data pointing to its 
efficacy limit its use.1 Moreover, nalidixic acid and ciprofloxacin 
are recommended for outpatient treatment. With regard to 
ciprofloxacin, although there is not a consensus,1 the Brazilian 
Ministry of Health imposes restrictions on its use in children.2 
Finally, nalidixic acid has been shown to have a low therapeutic 
efficacy, even when susceptibility of the etiologic agent is 
confirmed in vitro.1
In view of the above, as mentioned by Nunes et al., 9 indeed 
the use of sulfamethoxazole-trimethoprim for the empirical 
treatment of patients with dysentery in Brazil is not appropriate 
and should be restricted to cases for which antimicrobial 
susceptibility results are available. These data also suggest 
that the recommendation of the Ministry of Health regarding 
the use of this antimicrobial for the treatment of patients with 
shigellosis should be revised.
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